Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals NV

  • Price (EUR)49.20
  • Today's Change-0.80 / -1.60%
  • Shares traded20.00
  • 1 Year change-4.47%
  • Beta--
Data delayed at least 15 minutes, as of Jun 02 2023 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastroenterology and dermatology. It develops and manufactures products, which are distributed globally. The Company’s development pipeline is focused on Bowel Diseases, Colon Infections and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Its products include Lialda/Mezavant/Mesavancol and Uceri/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which develops for the treatment of travelers’ diarrhoea (TD), Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy; and Winlevi, which develops for the treatment of acne.

  • Revenue in CHF (TTM)99.34m
  • Net income in CHF16.76m
  • Incorporated--
  • Employees295.00
  • Location
    Cosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
  • Phone+353 18170370
  • Websitehttps://www.cosmopharma.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.